Price
No data yet.
Social Signal Score
Revenue
$-1.20M-364.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Laurence Rodriguez
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- 0.73
- Country
- FR
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.10
Financials
Revenue
$-1.20M-364.3%Net Income
$-10.19MEBITDA
$-8.61MFree Cash Flow
$-1.78MEPS (diluted)
$-0.05Shares Outstanding (diluted)
223.08M+2448.1%Operating Expenses
$7.41MCash & Debt
$1.67MReturn of Capital
$7.9KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $999.63 | $-12.03M | $-0.08 |
| 2024 | $1.50M | $-14.00M | $-0.17 |
| 2023 | $1.27M | $-26.22M | $-0.54 |
| 2022 | $2.58M | $-27.62M | $-0.60 |
| 2021 | $5.28M | $-28.62M | $-0.63 |
| 2020 | $4.39M | $-34.02M | $-0.97 |
| 2019 | $700.0K | $-30.71M | $-1.08 |
| 2018 | $4.35M | $-33.45M | $-1.37 |
| 2017 | $3.70M | $-24.11M | $-1.10 |
| 2016 | $3.00M | $-22.08M | $-1.36 |
| 2015 | $3.56M | $-13.65M | $-1.21 |
| 2014 | $1.10M | $-6.67M | $-0.75 |
| 2013 | $908.4K | $-2.76M | $-0.32 |
Valuation
GSGTFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·4h ago·Neutral
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, and the 15-20 National Hospital (l'Hôpital national des 15-20) in Paris t
View source ↗ - Newsbusinesswire.com·6h ago·Neutral
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and
View source ↗ - Newsbusinesswire.com·12h ago·Neutral
GenSight Biologics Reports Cash Position as of September 30, 2026 PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2026. Cash Position and Early Access Programs as of September 30, 2026 GenSight Biologics' cash and
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
GenSight Biologics Provides September 2026 Business Updates PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided business updates covering the summer of 2026 and confirmed the publication date for the Company's financial statement covering the first half o
View source ↗
Congress trades
No disclosed congressional trades in GSGTF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.